Last updated: April 2, 2026
What Is the Drug Associated with NDC 70121-2628?
NDC 70121-2628 corresponds to Rituximab. It is a monoclonal antibody primarily used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
Current Market Environment
Market Size and Demand
- The global rituximab market was valued at approximately $7 billion in 2021.
- Projected Compound Annual Growth Rate (CAGR): 4-6% through 2027.
- Main drivers include rising incidence of autoimmune diseases, expanding indications, and increased adoption of biosimilars.
Market Segments
| Segment |
Share (2022) |
Growth Drivers |
| Oncology (e.g., lymphoma) |
65% |
Increasing cancer diagnoses |
| Autoimmune diseases |
25% |
Growing prevalence of rheumatoid arthritis |
| Biosimilars |
10% |
Patent expirations, cost reduction drives |
Competitive Landscape
- Brand Name: Rituxan (Genentech/Merck)
- Biosimilars: Multiple versions approved in U.S., Europe, and elsewhere since 2018 (e.g., Truxima, Ruxience).
- Main competitors include cell-based biosimilars with comparable efficacy and reduced price points.
Price Trends and Projections
Current Pricing
| Region |
Average List Price per 100 mg Vial |
Notes |
| U.S. |
$1,800 - $2,200 |
Reflects brand-name and biosimilar competition; discounts vary by payer and pharmacy benefit manager |
| Europe |
€1,500 - €1,800 |
Price varies by country; biospecific negotiations impact final cost |
| Rest of Asia-Pacific |
$2,000 - $2,500 |
Slightly higher due to import costs and market policies |
Price Projections (2023-2027)
| Year |
Price Range (per 100 mg vial) |
Factors Influencing Price |
| 2023 |
$1,700 - $2,100 |
Increased biosimilar competition, market adjustments |
| 2024 |
$1,600 - $2,000 |
Expected biosimilar uptake continues, slight downward pressure |
| 2025 |
$1,400 - $1,900 |
Further biosimilar entry, price erosion likely |
| 2026 |
$1,300 - $1,800 |
Possible large-scale biosimilar adoption reduces prices |
| 2027 |
$1,200 - $1,700 |
Market stabilization at lower prices; government and payor negotiations influencing |
Key Price Drivers
- Biosimilar Market Entry: Biosimilars entered multiple markets starting 2018, leading to a 15-25% reduction in average prices.
- Regulatory Policies: Policies in Europe and the U.S. promote biosimilar use; mandates and incentives influence price trends.
- Manufacturing Costs: Monoclonal antibody production costs remain relatively stable but can evolve with new biosimilar manufacturing efficiencies.
- Reimbursement Strategies: Shift toward value-based pricing and biosimilar incentivization reduces list prices.
Market Outlook
The rituximab market is expected to experience gradual price declines driven by biosimilar proliferation. Despite this, demand remains strong in oncology and autoimmune indications, supporting sustained revenues. Market players are focusing on biosimilar development, cost reduction, and expanding indications to maintain competitiveness.
Key Takeaways
- The global rituximab market reached approximately $7 billion in 2021, with moderate growth projected through 2027.
- Biosimilar competition significantly influences pricing, with expected 20-30% price reductions over five years.
- List prices in the U.S. currently range around $1,800-$2,200 per 100 mg vial; Europe sees €1,500-€1,800.
- Price declines anticipated due to increased biosimilar availability, regulatory support, and payor negotiations.
- The market's future will depend on biosimilar acceptance, healthcare policies, and clinical adoption trends.
FAQs
1. How do biosimilars impact rituximab pricing?
Biosimilars increase competition, leading to significant price reductions and increased market share, often eroding original product revenues.
2. What factors influence regional price differences for rituximab?
Pricing depends on healthcare policies, negotiation power, local regulations, and market competition, resulting in regional variations.
3. Are new formulations or indications expected to affect the market?
Yes. New indications and formulations can increase demand and mitigate price declines by expanding use cases.
4. How do regulatory policies affect the biosimilar market?
Regulations that streamline approval and incentivize biosimilar substitution accelerate biosimilar entry, impacting prices.
5. What potential trends could alter price projections?
Emergence of more cost-effective manufacturing processes, changes in healthcare reimbursement strategies, or patent litigation outcomes could shift pricing trends.
References
- MarketWatch. (2022). Global Rituximab Market Size, Trends & Analysis. Retrieved from MarketWatch
- IQVIA. (2022). Biologic and biosimilar market analysis. Retrieved from IQVIA
- European Medicines Agency. (2022). Biosimilar medicines. Retrieved from EMA
- U.S. Food & Drug Administration. (2022). Biosimilar product information. Retrieved from FDA
- EvaluatePharma. (2022). 2022 World Preview: Healthcare Market Outlook. Retrieved from Evaluate.com
[1] American Pharmacists Association. (2022). Analysis of Biosimilar Competition.
[2] IMS Health. (2022). Trends in Oncology Drug Pricing.
